My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Catalog No: V0070
    CAS No. (CAS Registry Number): 1256589-74-8
    Description: Alectinib HCl (formerly AF802, CH5424802 or RO5424802; trade name ALECENSA) is a potent, selective, and orally bioavailable inhibitor of ALK (anaplastic lymphoma kinase)  tyrosi...
    Catalog No: V0154
    CAS No. (CAS Registry Number): 1032900-25-6
    Description: Ceritinib (formerly known as LDK378; trade name: Zykadia) is novel, potent and selective inhibitor against ALK (anaplastic lymphoma kinase positive) with potential anticanc...
    Catalog No: V0605
    CAS No. (CAS Registry Number): 761439-42-3
    Description: TAE684 (also called NVP-TAE684; TAE-684) is a novel, highly potent and selective small-molecule inhibitor of the ALK (anaplastic lymphoma kinase) tyrosine kinase with potential anticancer...
    Catalog No: V0606
    CAS No. (CAS Registry Number): 1256580-46-7 (free base)
    Description: Alectinib (formerly AF802, CH5424802, RO5424802; trade name Alecensa) is a potent, selective, and orally bioavailable ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor with poten...
    Catalog No: V0607
    CAS No. (CAS Registry Number): 1197953-54-0
    Description: Brigatinib (formerly AP26113; AP-26113; ALK-IN-1; trade name: Alunbrig) is an orally bioavailable, FDA-approved and selective ALK (anaplastic lymphoma kinase) inhibitor with pot...
    Catalog No: V0608
    CAS No. (CAS Registry Number): 1116235-97-2
    Description: GSK1838705A (GSK-1838705A) is a novel, potent and reversible small-molecule IGF-1R inhibitor with potential anticancer activity. It inhibits IGF-1R with IC50 of 2.0 nM. GSK18387...
    Products are for research use only;  We do not sell to patients
    Tel: 1-708-310-1919
    Fax: 1-708-557-7486
    Subscribe to our E-newsletter
    • Name*
    • *
    • E-mail*
    • *
    • instructions:
    • *
    Copyright 2020 InvivoChem LLC | All Rights Reserved